251 related articles for article (PubMed ID: 10024826)
1. [Antisense oligonucleotides are clinically tested. They inhibit the expression of disease-related genes].
Sommer W; Heilig M
Lakartidningen; 1999 Jan; 96(4):348-54. PubMed ID: 10024826
[TBL] [Abstract][Full Text] [Related]
2. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
Kausch I; Böhle A
Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
[TBL] [Abstract][Full Text] [Related]
3. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
Oberbauer R
Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
[TBL] [Abstract][Full Text] [Related]
4. Antisense technology and prospects for therapy of viral infections and cancer.
Wagner RW; Flanagan WM
Mol Med Today; 1997 Jan; 3(1):31-8. PubMed ID: 9021740
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic potential of antisense oligonucleotides.
Sharma HW; Narayanan R
Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
[TBL] [Abstract][Full Text] [Related]
6. Antisense therapy in malignant diseases: status quo and quo vadis?
Tamm I
Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotide therapy in urology.
Kausch I; Böhle A
J Urol; 2002 Jul; 168(1):239-47. PubMed ID: 12050550
[TBL] [Abstract][Full Text] [Related]
8. Antisense approaches to cancer gene therapy.
Mercola D; Cohen JS
Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254
[TBL] [Abstract][Full Text] [Related]
9. [Antisense oligonucleotides: a new therapeutic approach].
Guinot P; Temsamani J
Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
[TBL] [Abstract][Full Text] [Related]
10. [Applications of antisense oligonucleotides in oncology].
Pierga JY; Cammilleri S; Benyahia B; Magdelénat H
Bull Cancer; 1994 Dec; 81(12):1023-42. PubMed ID: 7742591
[TBL] [Abstract][Full Text] [Related]
11. Antisense therapy for cancer.
Gleave ME; Monia BP
Nat Rev Cancer; 2005 Jun; 5(6):468-79. PubMed ID: 15905854
[TBL] [Abstract][Full Text] [Related]
12. Oligonucleotide therapeutics: clothing the emperor.
Gewirtz AM
Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
[TBL] [Abstract][Full Text] [Related]
13. Nucleic-acid therapeutics: basic principles and recent applications.
Opalinska JB; Gewirtz AM
Nat Rev Drug Discov; 2002 Jul; 1(7):503-14. PubMed ID: 12120257
[TBL] [Abstract][Full Text] [Related]
14. Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides.
Morishita R; Tomita N; Kaneda Y; Ogihara T
Curr Opin Pharmacol; 2004 Apr; 4(2):139-46. PubMed ID: 15063357
[TBL] [Abstract][Full Text] [Related]
15. Antisense strategy in hematological malignancies.
Warzocha K
Cytokines Cell Mol Ther; 1999 Mar; 5(1):15-23. PubMed ID: 10390076
[TBL] [Abstract][Full Text] [Related]
16. Antisense oligonucleotide-based therapeutics for cancer.
Dean NM; Bennett CF
Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
[TBL] [Abstract][Full Text] [Related]
17. [Synthetic oligonucleotides and their application in gene therapy].
Iribarren AM
Medicina (B Aires); 1995; 55(3):263-6. PubMed ID: 8544726
[TBL] [Abstract][Full Text] [Related]
18. Antisense strategies for oncogene inactivation.
Stein CA; Benimetskaya L; Mani S
Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotide therapy in cancer.
Stephens AC; Rivers RP
Curr Opin Mol Ther; 2003 Apr; 5(2):118-22. PubMed ID: 12772500
[TBL] [Abstract][Full Text] [Related]
20. Towards genomic drug therapy with antisense oligonucleotides.
Lönnberg H; Vuorio E
Ann Med; 1996 Dec; 28(6):511-22. PubMed ID: 9017110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
